Angiogenic tumor vascular endothelial cells (ATVECs)

Angiogenic tumor vascular endothelial cells (ATVECs) represent the specialized population of endothelial cells that line the blood vessels within a tumor microenvironment. Unlike quiescent endothelial cells in healthy tissues, ATVECs are characterized by rapid proliferation, high migratory capacity, and structural abnormalities, such as gaps between cells and a lack of proper pericyte coverage (Source: National Cancer Institute, PubMed: 15660110). These cells are driven by the 'angiogenic switch,' where the tumor secretes pro-angiogenic factors like Vascular Endothelial Growth Factor (VEGF) to stimulate the formation of new blood vessels, which are essential for tumor growth beyond a few millimeters and for providing a route for metastasis (Source: StatPearls, NBK430744). Therapeutic strategies targeting these cells, known as anti-angiogenic therapies, aim to inhibit the signaling pathways (e.g., VEGF/VEGFR, Tie2/Angiopoietin) that sustain them, thereby 'starving' the tumor of nutrients or normalizing the vasculature to enhance the delivery of chemotherapy (Source: NIH/NCI). While highly effective in certain cancers, targeting ATVECs is associated with specific toxicities like hypertension and bleeding due to the systemic effects on the broader vascular system (Source: Journal of Clinical Oncology, DOI: 10.1200/JCO.2009.25.3120). This entry is marked as 'incorrect' because it describes a cell type rather than a specific molecular target (e.g., a protein or receptor).

Other names

Tumor-associated endothelial cellsTumor vascular endotheliumAngiogenic endotheliumTumor endothelial cells (TECs)

Inhibition of pro-angiogenic signaling pathways (primarily VEGF/VEGFR), induction of endothelial cell apoptosis, and normalization of tumor vasculature to improve drug delivery or starve the tumor of oxygen and nutrients.